Nature Communications (Dec 2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up

  • Michal Canetti,
  • Noam Barda,
  • Mayan Gilboa,
  • Victoria Indenbaum,
  • Michal Mandelboim,
  • Tal Gonen,
  • Keren Asraf,
  • Yael Weiss-Ottolenghi,
  • Sharon Amit,
  • Ram Doolman,
  • Ella Mendelson,
  • Dror Harats,
  • Laurence S. Freedman,
  • Yitshak Kreiss,
  • Yaniv Lustig,
  • Gili Regev-Yochay

DOI
https://doi.org/10.1038/s41467-022-35480-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Here the authors provide immunogenicity and efficacy data at 3-month follow-up for vaccinees who have received a fourth dose of either mRNA1273 or BNT162b2. Both vaccines were highly effective against substantial symptomatic disease, but had little effect against SARS-CoV-2 infection.